We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

112 hedge funds and large institutions have $187M invested in Provention Bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 51 increasing their positions, 18 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more call options, than puts

Call options by funds: $4.45M | Put options by funds: $1.21M

183% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 18

87% more capital invested

Capital invested by funds: $99.9M → $187M (+$87.1M)

3% less funds holding

Funds holding: 115 → 112 (-3)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

Holders
112
Holders Change
-3
Holders Change %
-2.61%
% of All Funds
1.93%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
51
Reduced
18
Closed
14
Calls
$4.45M
Puts
$1.21M
Net Calls
+$3.24M
Net Calls Change
+$919K

Top Buyers

Rank Fund Capital Flow
1
SC
Sessa Capital
New York
+$40.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$22.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.68M
4
BlackRock
BlackRock
New York
+$1.93M
5
PAI
Palo Alto Investors
California
+$1.78M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$617K
2
DCM
DG Capital Management
New York
-$562K
3
Goldman Sachs
Goldman Sachs
New York
-$530K
4
Verition Fund Management
Verition Fund Management
Connecticut
-$425K
5
JF
Jump Financial
Illinois
-$222K
Name Holding Trade Value Shares
Change 		Change in
Stake
TFGT
101
TS Financial Group (TSFG)
Illinois
$5K – – –
AA
102
Ancora Advisors
Ohio
$4K – – –
PNC Financial Services Group
103
PNC Financial Services Group
Pennsylvania
$3K – – –
CUAMC
104
China Universal Asset Management Company
China
$3K +$3.48K +764 New
CFGS
105
Concourse Financial Group Securities
Alabama
$2K – – –
PMFA
106
Plante Moran Financial Advisors
Michigan
$2K – – –
SPIA
107
Steward Partners Investment Advisory
New York
$2K – – –
TWA
108
TCI Wealth Advisors
Arizona
$2K – – –
PCA
109
Providence Capital Advisors
North Carolina
$1K – – –
JF
110
Jump Financial
Illinois
– -$222K -55,461 Closed
HF
111
HRT Financial
New York
– -$180K -45,043 Closed
Millennium Management
112
Millennium Management
New York
– -$170K -42,540 Closed
DU
113
Delphia (USA)
Ontario, Canada
– -$103K -25,698 Closed
CC
114
Corton Capital
Ontario, Canada
– -$94K -23,548 Closed
VF
115
Virtu Financial
New York
– -$71K -17,775 Closed
Cetera Investment Advisers
116
Cetera Investment Advisers
Illinois
– -$55K -13,800 Closed
PCM
117
Prelude Capital Management
New York
– -$48K -12,064 Closed
AL
118
Aspiriant LLC
California
– -$44K -11,000 Closed
DTL
119
Dynamic Technology Lab
Singapore
– -$42K -10,542 Closed
OMC
120
Old Mission Capital
Illinois
– -$41K -10,283 Closed
PHK
121
Point72 Hong Kong
Hong Kong
– -$21K -5,184 Closed
US Bancorp
122
US Bancorp
Minnesota
– -$12K -3,000 Closed
LC
123
Lindbrook Capital
California
– +$264 +58 New
1 2 3 4
5

PRVB Hedge Fund Activity: Q3 2022 in Review

112 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2022, worth a combined $187M — up 87% from $99.9M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of PRVB and 11 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 51 added.

The largest buyer was Sessa Capital, adding an estimated $40.5M. The largest seller was Renaissance Technologies, cutting an estimated $617K.

  • 112 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2022, down from 115 in Q2 2022.
  • Funds reported $187M of Provention Bio, Inc. Common Stock stock for Q3 2022, up 87% quarter-over-quarter.
  • 11 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2022 and 14 closed out, a net change of -3 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q3 2022 was Sessa Capital, an estimated $40.5M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $617K sold.

Based on aggregated 13F filings for Q3 2022.